Results 11 to 20 of about 100,944 (279)

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2

Critical Care Explorations, 2021
Objectives:. To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. Design:. Observational multicenter cohort study. Setting:.
Russell M. Petrak, MD, Nicholas W. Van Hise, PharmD, Nathan C. Skorodin, PharmD, Robert M. Fliegelman, DO, Vishnu Chundi, MD, Vishal Didwania, MD, Alice Han, MD, Brian P. Harting, MD, David W. Hines, MD   +8 more
doaj   +1 more source

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]

, 2020
Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra, Marcuzzi, Annalisa, Maximova, Natalia, Zanon, Davide   +3 more
core   +1 more source

Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center

Revista de Investigación Clínica, 2022
Background: Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results. Objective: The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with ...
Bernardo A. Martinez-Guerra, Nereyda A. de-León-Cividanes, Karla M. Tamez-Torres, Carla M. Román-Montes, Sandra Rajme-López, Edgar Ortiz-Brizuela, Carlos A. Aguilar-Salinas, Juan Sierra-Madero, José Sifuentes-Osornio, Alfredo Ponce-de-León, María F. González-Lara   +10 more
doaj   +1 more source

Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study

Antibiotics, 2022
(1) Background: The efficacy of tocilizumab in COVID-19 has been doubted. The study aimed to investigate factors affecting disease stability and response to tocilizumab among severe COVID-19 patients.
Wael Hafez, Ahmed Abdelrahman
doaj   +1 more source

An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy [PDF]

, 2015
Objective: To evaluate associations between lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity, at baseline and during treatment, with the risk of major adverse cardiovascular events (MACE) in tocilizumab‐treated patients with RA.
Bathon, Joan M., Giles, Jon T., Klearman, Micki, Lee, Janet S., Musselman, David, Pavlov, Andrey, Rao, Vijay U., Sattar, Naveed   +7 more
core   +1 more source

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab

Open Heart, 2023
Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with
Ola Kleveland, Rune Wiseth, Jan Kristian Damås, Pål Aukrust, Lars Gullestad, Bente Halvorsen, Einar Hopp, Kaspar Broch, T Ueland, Anne Kristine Anstensrud, Sindre Woxholt, Bjørn Bendz, Brage H Amundsen, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Ingvild Maria Tøllefsen, Liv Ryan, Tuva B Dahl, Camilla Huse   +19 more
doaj   +1 more source

Tocilizumab [PDF]

mAbs, 2009
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is ...
openaire   +2 more sources

Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

EClinicalMedicine, 2020
Background: Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage.
Nicola De Rossi, Cristina Scarpazza, Chiara Filippini, Cinzia Cordioli, Sarah Rasia, Chiara Rosa Mancinelli, Damiano Rizzoni, Giuseppe Romanelli, Stefania Cossi, Nereo Vettoretto, Sergio Bove, Silvano Manfredini, Eva Andrea Beindorf, Carlo Mosca, Vittorio Scipione, Gigliola Flamminio, Elena Albini Albini, Paola Giansiracusa, Ruggero Capra   +18 more
doaj   +1 more source

Eosinophilic fasciitis (Shulman's disease): review and comparative evaluation of seven patients. [PDF]

, 2019
OBJECTIVES: Eosinophilic fasciitis (EF) was described in 1974 by Shulman as a rare fibrosing connective tissue disease of unknown etiology. An undetermined trigger is thought to lead to the degranulation of eosinophils that interact with fibroblasts and
Cimbron, M, Farinha, F, Mendonça, T, Urzal, J   +3 more
core   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro, González-Fernández, María, Herrero, Alicia, Jiménez-Nácher, Inmaculada, Moreno, Francisco, Villamañán, Elena   +5 more
core   +3 more sources